Allogeneic hematopoietic stem cell transplantation (allo-HCT) is a curative therapeutic modality for patients with hematologic and non-hematologic illnesses. Despite the potential benefit, allo-HCT remains limited by complications including relapse, graft-versus-host disease (GVHD) and infection. Engraftment failure is another relatively uncommon complication of allo-HCT, but the incidence is increased with umbilical cord blood (UCB) 1 and T-cell-depleted 2 transplantation. We describe our experience with salvage haploidentical (haplo) allo-HCT following graft failure of a myeloablative (MA) T-cell-replete peripheral blood stem cell (PBSC) HCT in three patients: one patient received HLA-mismatched, unrelated graft and two received haplo HCT. Subsequent to graft loss, all patients were salvaged with a non-myeloablative (NMA) T-cell-replete haplo HCT using a fludarabine (FLU), cyclophosphamide (CY) and total body irradiation (TBI) 4 Gy (FLU/CY/TBI-4 Gy) regimen. GVHD prophylaxis was post-transplant cyclophosphamide (PTCy) 50 mg/kg (days +3 and +4), tacrolimus (day +5 to +180) and mycophenolate mofetil (MMF) (day +5 to +35). This approach is similar to previously used NMA haplo HCT regimens except for the use of a higher-dose TBI of 4 Gy instead of 2 Gy.
The first case is a 19-year-old male with paroxysmal nocturnal hemoglobinuria that progressed to hypoplastic myelodysplastic syndrome and was treated with eculizumab before transplant without response. He subsequently received a T-cell-replete haplo PBSC HCT from his father (CD34 + cell dose of 5 × 10 6 /kg) after MA conditioning consisting of busulfan (BU) (total AUC 16 000 μmol min/L) and FLU (160 mg/m 2 ) with GVHD prophylaxis of PTCy/tacrolimus/MMF. Donor-specific anti-HLA antibody (DSA) testing, performed by solid-phase assay, was negative before transplant. He failed to achieve engraftment until day +20 when his bone marrow (BM) biopsy was acellular, and chimerism studies, performed by short tandem repeat polymerase chain reaction, revealed only 3% CD3 + donor cells indicating primary graft failure. Viral PCR testing for cytomegalovirus (CMV), Epstein-Barr virus (EBV), human herpes virus 6 (HHV-6) and adenovirus were negative. He underwent a salvage HCT consisting of T-cell-replete haplo PBSC HCT from his mother on day +37 (CD34 + cell dose: 4.5 × 10 6 /kg) after a NMA regimen of FLU/CY/TBI-4 Gy) with GVHD prophylaxis of PTCy/tacrolimus/MMF. He achieved absolute neutrophil count engraftment on day +15 after the second transplant. His day +100 chimerism showed 100% donor cells. He developed chronic GVHD of the mouth, and liver (resolved with prednisone and rituximab therapy) and developed bronchiolitis obliterans (controlled by inhaled steroid therapy). He is currently alive at 30 months post second HCT without evidence of disease. The etiology of his primary graft failure was never identified.
The second case is a 33-year-old female diagnosed with secondary acute myeloid leukemia (AML) 3 years after receiving adriamycin, CY and docetaxel (adjuvant chemotherapy for breast cancer), who received 7+3 (idarubicin/cytarabine) induction (achieved first complete remission (CR1)) followed by two cycles of consolidation high-dose cytarabine. She underwent T-cell-replete haplo (brother) PBSC HCT (CD34 + cell dose of 6 × 10 6 /kg) after MA conditioning of BU (AUC 16 000)/FLU (160 mg/m 2 )/TBI 4 Gy with GVHD prophylaxis consisting of PTCy/tacrolimus/MMF. She was enrolled in a clinical trial using 'add-back' alpha-beta depleted T-cell boost that was infused on day +7. DSA test was negative before transplant. She experienced Escherichia coli sepsis on day +17, but responded to parental antibiotic therapy. By day +27, she had failed to achieve engraftment. BM biopsy demonstrated a hypoplastic marrow, with chimerism studies indicating donor CD3 + chimerism of only 1%, indicating primary graft failure. Viral PCR testing was positive for HHV-6 viremia (up to 23 000 copies/mL), which was treated with foscarnet until a negative titer was achieved. She subsequently underwent a salvage T-cell-replete haplo (mother-different donor) PBSC HCT (CD34+ cell dose of 7 × 10 6 /kg) on day +42 after NMA regimen of FLU/CY/TBI-4 Gy with GVHD prophylaxis consisting of PTCy/tacrolimus/MMF. She achieved absolute neutrophil count engraftment on day +14 after the second transplant. Her day +100 chimerism showed 100% donor's cells. She developed congestive heart failure with a left ventricular ejection fraction (LVEF) of 45% that normalized after 3 months with medical treatment. She experienced grade-I acute GVHD of the skin, resolved with topical steroids. She is alive 8 months after the second transplant with no evidence of the disease.
The third case is a 17-year-old female who developed secondary AML 5 years after receiving high-dose chemotherapy for osteosarcoma. She received induction therapy with cytarabine and etoposide and achieved CR1. She underwent BM transplantation from an HLA-A mismatched unrelated donor after a MA conditioning with BU/FLU/anti-thymocyte globulin (ATG) regimen. Despite achieving initial neutrophil engraftment on day +17, she developed persistent pancytopenia and was diagnosed with secondary graft failure on day +42 due to an aplastic marrow and complete loss of donor chimerism. BM viral PCRs (CMV, EBV, adenovirus, parvovirus-B19 and HHV-6), and viral culture were negative. She received salvage T-cell-replete haplo PBSC HCT from her mother with GVHD prophylaxis of PTCy/tacrolimus/MMF. Neutrophil engraftment occurred on day +20. She unfortunately developed respiratory failure requiring mechanical ventilation on day +44, with a bronchoalveolar lavage testing revealing Moraxella catarrhalis infection. Her clinical condition deteriorated and she expired on day +71 following the second transplant.
The utilization of T-cell-replete haplo HCT with PTCy GVHD prophylaxis has significantly expanded donor options. [3] [4] [5] The initial use of PTCy in T-cell-replete haplo HCT involved the use of BM graft after NMA conditioning regimen. 3 With that approach, patients who failed to engraft (2-13%) 3,4 frequently experienced autologous hematopoietic reconstitution, and thus survived engraftment failure. However, the high relapse rate (51% at 1 year) 3 using this approach prompted investigators to use MA regimens with either BM or PBSC grafts. The use of MA haplo HCT has been shown to be safe and effective in several studies, albeit with variable risk of engraftment failure of 0-13%. [6] [7] [8] [9] [10] [11] [12] Graft failure is often defined as failure of sustained hematopoiesis (absolute neutrophil count o 500/μL) by day +28 after transplant with aplastic BM picture (o 10% cellularity) in the absence of disease relapse. 13 Graft failure is often caused by inadequate stem cell (CD34 + ) dose, or poor survival/persistence of adequate stem cell dose, which could be due to infection (often viral, for example, CMV, adenovirus, HHV 6 and parvovirus), myelosuppressive medications (for example, ganciclovir or linezolid) or immune rejection by the host (for example, due to DSA). DSA testing before transplant is critical before performing any HCT from a mismatched donor. In our reported cases here, no patient exhibited a positive DSA testing before or after the first transplant.
Potential causes for graft failure were reviewed in all patients. Case #1 notably received no chemotherapy before the conditioning regimen; we thus suspected that inadequate host immunosuppression could have been a contributing factor for graft failure. Therefore, we opted to add 4 Gy of TBI in our subsequent BU/FLU MA conditioning regimen for haplo HCT. Despite successful engraftment in several other subsequent patients in our institution, case #2 failed to engraft (with evidence of HHV-6 viremia after the first transplant). It is unclear whether HHV-6 reactivation resulted in failure to engraft, or viral reactivation occurred because of the prolonged immunosuppression secondary to engraftment failure. The HHV-6 viremia in this patient was treated until complete resolution before receiving administration of the salvage transplant. Graft failure in patient #3 remains elusive with no clear explanation.
Overcoming engraftment failure following HCT remains a challenge. For example, previous data demonstrated that ATG-based haplo PBSC HCT can salvage engraftment failure after UCB transplant.
14 To our knowledge, the use of salvage haplo HCT using a T-cell-replete PBSC graft has not been systematically studied.
As demonstrated by these clinical cases, engraftment failure can be successfully salvaged using a NMA regimen with T-cell-replete PBSC haplo HCT followed by PTCy GVHD prophylaxis. Two of these three patients received an initial T-cell-replete haplo HCT after MA conditioning regimen, and PTCy GVHD prophylaxis. A repeat course of PTCy (50 mg/kg on day +3 and +4) was well tolerated, albeit one patient developed reversible reduction of LVEF (she had also received prior anthracyclines for breast cancer and AML induction). The third case with early secondary graft failure after a mismatched, unrelated donor HCT was also salvaged with the same strategy, but unfortunately succumbed to infectious complications after achieving engraftment from the second transplant.
On the basis of these small numbers, the authors cannot make a conclusion on whether it is appropriate to use the same or a different haplo-identical donor. A prior study revealed no difference in transplant outcomes for patients receiving the same versus different donors in the setting of graft failure of HLA-matched, unrelated donors. 13 In our reported patients, although the DSA test was negative after haplo-transplant in both patients 1 and 2, we opted to use a different haplo donor. We believe that a key factor for successful salvage HCT is early workup to treat underlying viral infection (if any) and to prepare the donor for donation. In our first two cases (primary engraftment failure), salvage HCT was done on day +37 and +42 after the first transplant.
In conclusion, NMA T-cell-replete haplo PBSC HCT with PTCy GVHD prophylaxis can be considered to salvage patients with engraftment failure after prior MA HCT.
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